Lung Disease News and Research RSS Feed - Lung Disease News and Research

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine. [More]
SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit. [More]
Teenagers uncertain about the harmful effects of marijuana or e-cigarettes

Teenagers uncertain about the harmful effects of marijuana or e-cigarettes

Teenagers are very familiar with the risks of smoking cigarettes, but are much less sure whether marijuana or e-cigarettes are harmful, according to a new study by researchers at the Stanford University School of Medicine. [More]
UT Southwestern researchers identify two proteins within fetal lungs that initiate labor process

UT Southwestern researchers identify two proteins within fetal lungs that initiate labor process

Researchers at UT Southwestern Medical Center have identified two proteins in a fetus' lungs responsible for initiating the labor process, providing potential new targets for preventing preterm birth. [More]
Long-term smokers and ex-smokers have respiratory-related impairments

Long-term smokers and ex-smokers have respiratory-related impairments

More than half of long-term smokers and ex-smokers who are considered disease-free because they passed lung-function tests have respiratory-related impairments when more closely evaluated with lung imaging, walking and quality-of-life tests. Many of those people likely have the earliest stages of chronic obstructive pulmonary disease, an incurable progressive disease (COPD) that is the third leading cause of death in the United States. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
Autoantibodies play major role in IPF patients with acute exacerbations

Autoantibodies play major role in IPF patients with acute exacerbations

Patients with acute exacerbations of idiopathic pulmonary fibrosis responded well to therapies similar to those used to treat autoimmune diseases, according to findings published today in PLOS ONE. The study suggests that autoantibodies — implicated in many autoimmune diseases such as rheumatoid arthritis or lupus — also play an important role in patients with acute exacerbations of IPF, a devastating lung disease. [More]
Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix announces new inhaled anti-infective therapy to treat CF-associated fungal infections

Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF). [More]
Researchers examine proteins on surface of naive CD4+ T cells

Researchers examine proteins on surface of naive CD4+ T cells

The team headed by Dr. Kathrin Suttner, who, together with Prof. Dr. Carsten Schmidt-Weber, heads the airway immunology research group at the Helmholtz Zentrum München and Technische Universität München, concentrated its work on the so-called naive CD4+ T cells. [More]
A gastroenterologist guide to probiotics

A gastroenterologist guide to probiotics

In recent years, scientists have introduced us to a paradigm shift in the microscopic world. We've moved from thinking about all bacteria as bad guys to be wiped out with antibiotics and hand sanitizer to recognizing that some microbes are helpers, good bacteria that live in our GI tract (and all over our bodies) that keep us healthy. [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
Detecting blood clots with a portable device

Detecting blood clots with a portable device

Blockages in lung arteries could be diagnosed safely in real-time helping as many as 20,000 respiratory patients in Australia each year with emerging technology being developed by electrical engineering researchers at the University of Sydney. [More]
New therapeutic target discovered for idiopathic pulmonary fibrosis

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected. [More]
Experimental Zephyr endobronchial valve provides good result in emphysema patient at UAB

Experimental Zephyr endobronchial valve provides good result in emphysema patient at UAB

In late March, physicians at the University of Alabama at Birmingham carefully threaded a one-way valve the size of a black-eyed pea into the lower lobe of Dennis Bullock's left lung. Bullock, a 67-year-old emphysema patient, was the fourth person at UAB to receive the experimental Zephyr endobronchial valve. [More]
Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

Use of antidepressants in late pregnancy may be associated with increased risk of PPHN

An analysis of approximately 3.8 million pregnancies finds that use of antidepressants late in pregnancy may be associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN), according to a study in the June 2 issue of JAMA. However, the absolute risk was small and the risk increase appears more modest than suggested in previous studies. [More]
Childhood trauma increases vulnerability to different health problems in later life

Childhood trauma increases vulnerability to different health problems in later life

Long-term changes in immune function caused by childhood trauma could explain increased vulnerability to a range of health problems in later life, according to new research by the Institute of Psychiatry, Psychology & Neuroscience at King's College London and the NIHR Maudsley BRC. [More]
Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib. [More]
Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015. [More]

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus. [More]
Advertisement
Advertisement